Denali Therapeutics Stock Performance

DNLI Stock  USD 19.82  1.02  4.89%   
On a scale of 0 to 100, Denali Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 2.01, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. Please check Denali Therapeutics' potential upside, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Denali Therapeutics' price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Denali Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating essential indicators, Denali Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(1.14)
Five Day Return
(5.19)
Year To Date Return
28.09
Ten Year Return
(2.84)
All Time Return
(2.84)
1
Acquisition by Thornberry Nancy of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3
11/21/2025
2
Denali Therapeutics announces board and leadership changes By Investing.com - Investing.com Nigeria
11/28/2025
3
Does Denali Therapeutics Discounted Equity Raise Reveal a New Phase in Its Risk Strategy
12/16/2025
4
Acquisition by Ryan Watts of 236880 shares of Denali Therapeutics at 16.27 subject to Rule 16b-3
01/02/2026
5
Acquisition by Schuth Alexander O. of 57700 shares of Denali Therapeutics subject to Rule 16b-3
01/05/2026
6
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
01/06/2026
7
Assessing Denali Therapeutics Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review
01/08/2026
8
Denali Therapeutics Inc. Stock Analysis Exploring An 83 percent Upside Potential - DirectorsTalk Interviews
01/13/2026
9
3 Biotech Stocks That Could Double In 2026 - AOL.com
01/20/2026
10
Acquisition by Klein Peter S of 6037 shares of Denali Therapeutics subject to Rule 16b-3
01/28/2026
11
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcomi...
01/29/2026
12
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium
02/02/2026
13
Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium
02/05/2026
14
Assessing Denali Therapeutics Valuation After WORLDSymposium Clinical Updates And Regulatory Progress
02/09/2026
Begin Period Cash Flow128.7 M
Total Cashflows From Investing Activities-88.8 M
Free Cash Flow-363.6 M

Denali Therapeutics Relative Risk vs. Return Landscape

If you would invest  1,752  in Denali Therapeutics on November 12, 2025 and sell it today you would earn a total of  230.00  from holding Denali Therapeutics or generate 13.13% return on investment over 90 days. Denali Therapeutics is currently generating 0.2727% in daily expected returns and assumes 3.7955% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Denali, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Denali Therapeutics is expected to generate 4.69 times more return on investment than the market. However, the company is 4.69 times more volatile than its market benchmark. It trades about 0.07 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of risk.

Denali Therapeutics Target Price Odds to finish over Current Price

The tendency of Denali Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 19.82 90 days 19.82 
about 19.57
Based on a normal probability distribution, the odds of Denali Therapeutics to move above the current price in 90 days from now is about 19.57 (This Denali Therapeutics probability density function shows the probability of Denali Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.01 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Denali Therapeutics will likely underperform. Additionally Denali Therapeutics has an alpha of 0.397, implying that it can generate a 0.4 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Denali Therapeutics Price Density   
       Price  

Predictive Modules for Denali Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Denali Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
17.1220.8924.66
Details
Intrinsic
Valuation
LowRealHigh
18.7626.9930.76
Details
19 Analysts
Consensus
LowTargetHigh
29.9032.8636.47
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.82-0.76-0.72
Details

Denali Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Denali Therapeutics is not an exception. The market had few large corrections towards the Denali Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Denali Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Denali Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.40
β
Beta against Dow Jones2.01
σ
Overall volatility
1.89
Ir
Information ratio 0.12

Denali Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Denali Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Denali Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Denali Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (422.77 M) with loss before overhead, payroll, taxes, and interest of (420.66 M).
Denali Therapeutics currently holds about 1.07 B in cash with (347.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Over 96.0% of the company shares are held by institutions such as insurance companies
Latest headline from simplywall.st: Assessing Denali Therapeutics Valuation After WORLDSymposium Clinical Updates And Regulatory Progress

Denali Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Denali Stock often depends not only on the future outlook of the current and potential Denali Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Denali Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding164.5 M
Cash And Short Term Investments832.3 M

Denali Therapeutics Fundamentals Growth

Denali Stock prices reflect investors' perceptions of the future prospects and financial health of Denali Therapeutics, and Denali Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Denali Stock performance.

About Denali Therapeutics Performance

By evaluating Denali Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Denali Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Denali Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Denali Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand(49.46)(51.93)
Return On Tangible Assets(0.28)(0.29)
Return On Capital Employed(0.34)(0.36)
Return On Assets(0.28)(0.29)
Return On Equity(0.40)(0.38)

Things to note about Denali Therapeutics performance evaluation

Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Denali Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (422.77 M) with loss before overhead, payroll, taxes, and interest of (420.66 M).
Denali Therapeutics currently holds about 1.07 B in cash with (347.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Over 96.0% of the company shares are held by institutions such as insurance companies
Latest headline from simplywall.st: Assessing Denali Therapeutics Valuation After WORLDSymposium Clinical Updates And Regulatory Progress
Evaluating Denali Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Denali Therapeutics' stock performance include:
  • Analyzing Denali Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Denali Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Denali Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Denali Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Denali Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Denali Therapeutics' stock. These opinions can provide insight into Denali Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Denali Therapeutics' stock performance is not an exact science, and many factors can impact Denali Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
CEOs Directory
Screen CEOs from public companies around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital